Biologics has revolutionized the treatment strategy of rheumatoid arthritis(RA) and improved the clinical outcome. On the other hand, the medication cost of biologics has become a substantial socioeconomic burden. Researchers are now discussing the strategies to optimize the use of biologics, which include the dose reduction/discontinuation of biologics. A pilot study suggests that musculoskeletal ultrasound determines 'deep remission' and predicts relapse after discontinuation of biologics more accurately than does clinical assessment. The perspective of ultrasound-guided strategy to reduce/discontinue biologics is discussed.